Search - tctmd.com

Displaying 701 - 720 of 901

Sort: Relevancy | Date

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Physically Active Less Likely to Die After MI Than Sedentary Individuals

Michael O'Riordan

April 14, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Daily News

Intracoronary Shot of Morphine Fails to Limit Myocardial Infarct Size

Michael O'Riordan

April 07, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

Advertisement

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Who Should Get a Statin? Guidelines Don’t Match Up

One in Five Acute MI Patients Drop Statins Within 2 Years

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Physically Active Less Likely to Die After MI Than Sedentary Individuals

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Intracoronary Shot of Morphine Fails to Limit Myocardial Infarct Size

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content